The earnings call highlighted significant clinical progress and operational efficiencies, particularly in iNKT therapies, with strategic partnerships and upcoming trials indicating a positive outlook. However, financial strains such as increased net loss and limited cash reserves present challenges.

Company Guidance -

Q3 2025

During MiNK Therapeutics' Second Quarter 2025 Conference Call, the company highlighted significant milestones and provided forward-looking guidance. They reported a complete clinical response in a 49-year-old patient with metastatic testicular cancer, showcasing the potential of their iNKT platform. The company also achieved a 30% year-over-year reduction in operating cash burn, extending their financial runway beyond mid-2026. MiNK's strategic focus includes advancing their iNKT programs in oncology and immune-mediated diseases, with ongoing Phase II trials and new trials anticipated in graft-versus-host disease (GvHD) and acute respiratory distress syndrome (ARDS). Financially, the company raised an additional $13 million, bolstering their cash balance to $1.7 million and extending their runway through mid-2026. They also reported a net loss of $4.2 million for Q2 2025. The call emphasized the potential of their iNKT therapies and ongoing strategic partnerships to address unmet medical needs and enhance shareholder value.

Complete Clinical Response in Metastatic Testicular Cancer

Reported a durable complete remission in a 49-year-old man with metastatic testicular cancer using agenT-797, achieving sustained remission for more than 2 years without cytokine release syndrome or GvHD.

Reduction in Operating Cash Burn

Achieved a reduction in Q2 operating cash burn by over 30% year-over-year, reflecting operational efficiencies.

Advancement in iNKT Therapies

Momentum in late-stage strategic partnership discussions and increased market capitalization following positive publication in Nature's Oncogene.

Phase II and III Trials Planned

Ongoing and upcoming trials for gastric cancer, GvHD, and ARDS with external funding support, signaling robust pipeline progression.

MiNK Therapeutics (INKT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INKT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.96 / -	-0.5	―	―	―
Aug 14, 2025	2025 (Q2)	-0.55 / -1.06	-0.7	-51.43% (-0.36)	―
May 15, 2025	2025 (Q1)	-0.61 / -0.70	-1.1	36.36% (+0.40)	―
Mar 18, 2025	2024 (Q4)	-0.49 / -0.62	-1.6	61.25% (+0.98)	―
Nov 14, 2024	2024 (Q3)	-0.80 / -0.50	-1.5	66.67% (+1.00)	―
Aug 13, 2024	2024 (Q2)	-0.98 / -0.70	-1.8	61.11% (+1.10)	―
May 14, 2024	2024 (Q1)	-1.52 / -1.10	-1.7	35.29% (+0.60)	―
Mar 21, 2024	2023 (Q4)	-1.52 / -1.60	-2.3	30.43% (+0.70)	―
Nov 09, 2023	2023 (Q3)	-1.82 / -1.50	-1.9	21.05% (+0.40)	―
Aug 10, 2023	2023 (Q2)	-1.98 / -1.80	-1.8	0.00% (0.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INKT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$17.50	$15.32	-12.46%
May 15, 2025	$7.50	$7.18	-4.27%
Mar 18, 2025	$8.52	$8.24	-3.29%
Nov 14, 2024	$7.94	$7.50	-5.54%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mink Therapeutics, Inc. (INKT) report earnings?

Mink Therapeutics, Inc. (INKT) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Mink Therapeutics, Inc. (INKT) earnings time?

Mink Therapeutics, Inc. (INKT) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INKT EPS forecast?

INKT EPS forecast for the fiscal quarter 2025 (Q3) is -0.96.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing